(04-04-12) Differential effects of low-dose resveratrol on adiposity and hepatic steatosis in diet-induced obese mice.

Cho SJ, Jung UJ, Choi MS.
Source
Department of Food Science and Nutrition, Kyungpook National University, 1370
Sankyuk Dong Puk-ku, 702-701 Daegu, Republic of Korea.
Abstract
Consumption of a high-fat diet (HFD) enriched in saturated fat induces
excessive weight gain due to adiposity, which can lead to metabolic
complications, as well as increased risk of fatty liver disease and CVD. The
present study investigated the underlying mechanism and dose-response effects
of resveratrol (RV) on obesity, hepatic steatosis and dyslipidaemia in mice fed
a HFD. Male C57BL/6J mice were fed a normal diet or a HFD (20 % fat, w/w)
combined with 0?005 or 0?02 % (w/w) RV for 10 weeks. As expected, mice fed a
HFD developed obesity, as shown by increased body weight gain, visceral fat,
hepatic fat and plasma cholesterol. RV significantly reduced visceral fat and
plasma NEFA. In the liver of HFD-fed mice, RV significantly reduced TAG and
cholesterol, as well as lipid droplet number and size. A low dose of RV (0?005
%) appeared to be more effective than a higher dose of RV (0?02 %) for
suppressing adiposity and hepatic steatosis development with a significant
decrease in body weight gain, plasma TAG and total cholesterol levels. These
changes were seemingly attributable to a suppression of the fatty acid (FA)
synthase, glucose-6-phosphate dehydrogenase, and phosphatidate phosphohydrolase
and/or an activation of FA oxidation in the liver and epididymal adipose
tissue. In conclusion, daily consumption of a low dose of RV is effective for
protecting against diet-induced obesity, hepatic steatosis and dyslipidaemia in
HFD-fed mice.

Source: Br J Nutr. 2012 Mar 14:1-10. [Epub ahead of print]

News

---

In evidenza

"L'informazione presente nel sito serve a migliorare, e non a sostituire, il rapporto medico-paziente."

Per coloro che hanno problemi di salute si consiglia di consultare sempre il proprio medico curante.